文章：

重新评估第14天骨髓活检在急性髓系白血病中的作用

Revisiting the Role of Day 14 Bone Marrow Biopsy in Acute Myeloid Leukemia

原文发布日期：6 March 2025

DOI: 10.3390/cancers17050900

类型: Article

开放获取: 是

英文摘要：

In recent years, the practice of routinely obtaining day 14 bone marrow biopsies during AML intensive induction therapy has been scrutinized. While current guidelines recommend obtaining mid-induction biopsies to gauge early response to treatment and guide potential changes in future management, concerns have been raised that these biopsies may not be as prognostically accurate as hoped and subsequently may result in additional and unwarranted chemotherapy toxicity in select patients. In this review, our goal is to summarize the most recent evidence surrounding day 14 bone marrow biopsies that have been published and clarify the utility of this currently recommended practice. Here, we review major developments in mid-induction biopsy in AML, along with ongoing and future planned studies in this area, outlining the limitations of available data and our future goals.

摘要翻译： 

近年来，急性髓系白血病强化诱导治疗期间常规进行第14天骨髓活检的临床实践受到审视。尽管现行指南建议通过诱导中期活检评估早期治疗反应并指导后续治疗方案的潜在调整，但有观点认为此类活检的预后准确性可能未达预期，且可能导致部分患者承受不必要的额外化疗毒性。本文旨在综述已发表的最新证据，阐明当前推荐实践的临床价值。我们将系统回顾AML诱导中期活检的主要研究进展，梳理该领域正在进行及计划开展的研究项目，同时指出现有数据的局限性并展望未来研究方向。

原文链接：

Revisiting the Role of Day 14 Bone Marrow Biopsy in Acute Myeloid Leukemia